top of page
OBJECTIVE: To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS).
DESIGN: Case report.
SETTING: Academic clinical practice and General Clinical Research Center.
PATIENT(S): A 25-year-old woman with PCOS.
INTERVENTION(S): Rosiglitazone maleate, 4 mg daily for 5 months until conception.
MAIN OUTCOME MEASURE(S): Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images.
RESULT(S): Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception.
CONCLUSION(S): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.
Cataldo NA et al., 2001
Cataldo NA, Abbasi F, McLaughlin TL, Lamendola C, Reaven GM
bottom of page